PAR-25-070-Full-Announcement.html

This document is a Request for Application (RFA) for the federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)".

The goal of this funding opportunity is to promote preclinical and patient-based studies examining the mechanisms through which incretin mimetics (GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to attract scientists to investigate how these agents influence cancer risk. The funding is being provided by the Department of Health and Human Services National Institutes of Health under the Cancer Cause and Prevention Research program (CFDA 93.393). Eligible applicant types include state/local governments, higher education institutions, non-profits, small businesses, and other organizations. The funding instrument is a grant. No clinical trials are allowed under this opportunity. The application deadline and award dates are not specified in the document provided.